Can a computer predict your lung cancer treatment success?
NCT ID NCT04944030
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is collecting data from 200 people with advanced lung cancer to build computer models that could predict how well a treatment will work. Researchers will gather information from tumor biopsies, blood and urine samples, and patient questionnaires about quality of life and emotions. The goal is to better understand why some treatments work and others don't, but this study does not test any new drug or therapy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to computer models that help doctors predict which lung cancer treatments will work best for each patient.
- What could go wrong
- This is an early observational study, not testing a treatment. The models may not prove accurate enough to change patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2023
- Expected to finish
-
Oct 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening biopsy, blood sample and questionnaires * 18 years old at time of written consent * Patient with histologically confirmed lung cancer * Lung cancer metastatic disease or locally advanced not eligible for local curative treatment intent * Performance status ≤ 2 (according to WHO criteria) * Indication of any systemic therapeutic strategy can be performed alongside this current cohort in accordance with national and / or international recommendations. * Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up. * Patient must be affiliated to a Social Health Insurance Exclusion Criteria: * Other malignancy treated within the last 3 years (except non-melanoma skin cancer or in situ carcinoma of the cervix) * Other neuroendocrine tumour than small cell or large cell carcinoma. * Pregnant or nursing patient * Individual deprived of liberty or placed under the authority of a tutor * Impossibility to submit to the medical follow-up of this clinical trial for geographical, social or psychological reasons
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Institut de Cancerologie de L'Ouest
RECRUITINGAngers, 49933, France
-
Institut de Cancerologie de L'Ouest
RECRUITINGSaint-Herblain, 44805, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A spoonful of olive oil before lung surgery: a new shield against a rare complication?
- Mobile lung cancer clinics aim to close rural screening gap
- Can protein patterns in stored tumors point to new treatment targets?
- Lung surgery without a breathing tube: a gentler path to recovery?
- A single blood draw to detect five cancers before symptoms appear?
- A breath sniff could one day screen for lung cancer and more